Fulgent Genetics (FLGT) Depreciation & Amortization (CF) (2015 - 2026)

Fulgent Genetics has disclosed Depreciation & Amortization (CF) across 12 years of filings, most recently posting $6.0 million for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $6.0 million, up 1.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.1 million (down 0.81% YoY), and the FY2025 annual result was $24.1 million, down 3.23% from the prior year.
• Depreciation & Amortization (CF) came in at $6.0 million for Q1 2026 at Fulgent Genetics, down from $6.1 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $9.8 million in Q3 2022 to a low of $110000.0 in Q3 2025.
• The 5-year median for Depreciation & Amortization (CF) is $6.2 million (2024), against an average of $6.0 million.
• Across the five-year window, Depreciation & Amortization (CF) surged 245.12% in 2022 and plunged 97.37% in 2024, its largest moves.
• Fulgent Genetics' Depreciation & Amortization (CF) stood at $9.8 million in 2022, then tumbled by 33.35% to $6.5 million in 2023, then fell by 5.22% to $6.2 million in 2024, then decreased by 1.29% to $6.1 million in 2025, then slipped by 1.83% to $6.0 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $6.0 million (Q1 2026), $6.1 million (Q4 2025), and $110000.0 (Q3 2025), per Business Quant data.